European healthtech and medtech face a new funding landscape in 2026

European health technology and medical technology companies are entering 2026 in a very different market from the one that fuelled their earlier growth. What had looked, in the boom years, like a broadly expanding venture ecosystem is now more selective, more capital-intensive and far less forgiving of weak business models. The result is a clear divide: a small group of well-positioned leaders continues to attract money, while many mid-stage companies struggle to progress beyond Series A.

That tightening is not unique to healthcare. A World Fund report on European climate tech describes a similar Series B funding gap, with average rounds smaller than those in the US and too few mid-sized funds able to lead growth investments in the $25 million to $100 million range. In healthtech and medtech, the same structural issue is visible in a market that increasingly rewards scale, proof and defensibility rather than promise alone.

The picture is still not one of collapse. EY’s latest review of France’s healthtech sector showed companies raised €2.3 billion in 2025, even if that marked a decline from the previous year, while venture capital activity across the country remained resilient. Across Europe, funding remains concentrated in a handful of markets: the UK, France, Switzerland, Germany, the Netherlands, Sweden and Denmark together accounted for most of the capital raised, underlining how regional leadership is narrowing around established hubs.

What has changed most is investor behaviour. According to the broader European healthtech outlook published by Healthcare.Digital, the sector has moved from speculative fragmentation to a more disciplined phase of industrial maturity. Backers now want evidence that products are embedded in clinical workflows, produce measurable efficiency gains and can move toward profitability without endless follow-on capital. The old assumption that a successful seed or Series A would naturally lead to an easy Series B has largely broken down.

That has left many founders confronting what market participants increasingly describe as a Series B crunch. Fundraising is taking longer, milestone requirements are harder, and the pool of investors willing to lead mid-stage rounds has thinned. A growing share of capital is being channelled into companies already seen as de-risked, while weaker businesses are pushed toward consolidation, distressed sales or closure.

The consequences are reshaping the M&A market as well. Venture-to-venture acquisitions, in which one startup buys another, are becoming more common as smaller companies seek exits before capital runs out. At the same time, strategic buyers are favouring bolt-on deals that strengthen existing product lines rather than speculative bets on unfinished technology. Private equity is also becoming more active, but typically where revenue is predictable and integration risk is manageable.

Europe’s regulatory environment is amplifying that trend. The Medical Device Regulation and In Vitro Diagnostic Regulation have raised the bar on clinical evidence, quality systems and post-market surveillance, making compliance more expensive and time-consuming. That burden has slowed launches, pushed some firms to prioritise other geographies and, in some cases, led manufacturers of niche devices to discontinue products altogether. The European Commission’s targeted revision proposal, published in December 2025, aims to ease some of that pressure by simplifying processes and improving predictability without lowering safety standards.

Artificial intelligence is adding another layer of complexity. Many medical AI tools now fall into the high-risk category under the EU AI Act, but the latest policy direction appears to be to keep most of the conformity burden within the existing medical device framework rather than layering duplicate assessments on top. For companies already holding the right certifications, that can turn regulatory readiness into a competitive asset rather than just a cost of doing business.

The financing landscape is also being reshaped by foreign capital, especially from the United States. Healthcare.Digital describes a strong “American” influence in late-stage European rounds, with US investors taking a growing share of participation in deals and often underwriting the largest financings. Recent headline transactions, including large rounds for Neko Health and Isomorphic Labs, illustrate how global appetite is concentrating around a small number of businesses considered capable of scaling well beyond Europe. That influx helps close the funding gap, but it also raises questions about whether current valuations can be sustained if exits do not keep pace.

Technology itself is not enough to command premium pricing anymore. Companies are being rewarded for interoperability, recurring revenue, real-world evidence and workflow integration. In practical terms, that means products that reduce administrative burden, speed up collections, improve clinical throughput or fit cleanly into existing electronic health record systems are likely to fare better than standalone tools that require heavy behavioural change from hospitals.

That shift is visible in the kinds of businesses attracting attention. Consumer health platforms, data-rich diagnostics and AI-enabled workflow software are still drawing interest, but so are companies with stronger infrastructure characteristics: proprietary datasets, regulatory approvals, embedded distribution and clear operational use cases. The market is effectively moving towards platforms rather than point solutions.

For founders, the implications are stark. Capital efficiency matters more than growth-at-any-cost metrics. Clinical proof matters more than narrative. And a defensible position in a regulated market may now be worth more than rapid expansion without evidence of adoption. For investors, the challenge is to identify which businesses can become enduring infrastructure and which are simply the latest iteration of a crowded category.

The European healthtech and medtech sector remains resilient, but resilience is no longer the same thing as easy funding. The market is maturing under pressure, and that is forcing a reordering of value. Those able to combine regulation, workflow integration and measurable outcomes are likely to define the next phase. Those that cannot may find the Series B gap is less a funding pause than a permanent dividing line.